ID   CDina26
AC   CVCL_A0IM
SY   BT 5/9; BT5/9; 5/9
DR   ABCD; ABCD_AA723
DR   Wikidata; Q108820000
RX   Patent=US9376498;
RX   Patent=US10208126;
RX   PubMed=6459366;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 12002.
CC   Biotechnology: Was used to produce the monoclonal antibody begelomab (Begedina) which was evaluated as a therapeutic agent against steroid-resistant acute graft-versus-host disease.
CC   Monoclonal antibody isotype: IgG2b.
CC   Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_3412 ! P3X63Ag8U.1
CA   Hybridoma
DT   Created: 23-09-21; Last updated: 21-03-23; Version: 3
//
RX   Patent=US9376498;
RA   Di Naro A.F.;
RT   "Anti-CD26 antibodies and uses thereof.";
RL   Patent number US9376498, 28-Jun-2016.
//
RX   Patent=US10208126;
RA   Di Naro A.F.;
RT   "Methods of treating aplastic anemia by administering anti-CD26
RT   antibodies.";
RL   Patent number US10208126, 19-Feb-2019.
//
RX   PubMed=6459366; DOI=10.4049/jimmunol.128.1.16;
RA   Corte G., Mingari M.C., Moretta A., Damiani G., Moretta L.,
RA   Bargellesi A.;
RT   "Human T cell subpopulations defined by a monoclonal antibody. I. A
RT   small subset is responsible for proliferation to allogeneic cells or
RT   to soluble antigens and for helper activity for B cell
RT   differentiation.";
RL   J. Immunol. 128:16-19(1982).
//